Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
April 7, 2026Pamplona/MadridIn recruitment
DS6000-109 Clinical trial to evaluate raludotatug deruxtecan (R-DXd) in participants with rapidly progressing ovarian cancer, primary peritoneal cancer, or platinum-resistant fallopian tube cancer.
The primary objective is to evaluate raludotatug deruxtecan, also known as R-DXd, at each dose level. -
April 6, 2026Pamplona/MadridIn recruitment
GRWD5769-ST-01 A study focusing on the ERAP-1-mediated immunopeptidome.
The primary objective of this clinical trial is to determine the safety and efficacy of the study drug 12GRWD5769, either alone or in combination with another drug called Libtayo® (cemiplimab), in the treatment of advanced or metastatic solid tumors. -
April 6, 2026Pamplona/MadridIn recruitmentEarly phase
GEM-CAR-HIRISMM A Phase II, open-label, single-arm, multicenter study of Ciltacabtagene Autoleucel in high-risk quiescent multiple myeloma
The aim of this study is to investigate the safety and efficacy of the Dara-VRD regimen followed by Ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy, in patients diagnosed with high-risk MMq. -
March 24, 2026Pamplona/MadridIn recruitment
BNT326-02 A Phase Ib/II, multicenter, open-label clinical trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer.
The purpose of this trial is: to investigate a potential new combination of trial drugs (consisting of the trial drug, which is an antibody-drug conjugate [ADC] called BNT326, in combination with an immunotherapy drug, BNT327) to determine the recommended dose of the trial drug; to evaluate the safety of the combination of study drugs; and to obtain information on its efficacy for advanced or metastatic NSCLC. -
March 24, 2026Pamplona/MadridIn recruitment
18-BI-1206-03 A Phase I/IIa clinical trial of BI-1206, a monoclonal antibody targeting CD32b (Fc?RIIB), in combination with pembrolizumab, in patients with advanced solid tumors.
The aim is to determine whether the drug BI-1206, which has not yet been approved for marketing, will be effective in treating advanced solid tumors and how safe it is for people. In this study, BI-1206 will be administered in combination with pembrolizumab, an approved drug marketed as Keytruda -
March 24, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-003 A randomized, double-blind, phase 2b comparative clinical trial investigating the efficacy and safety of visugromab compared with placebo
The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy -
March 17, 2026Pamplona/MadridIn recruitment
D7029C00001 A Phase III, randomized, open-label, sponsor-blinded, multicenter clinical trial of rilvegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment in patients with advanced hepatocellular carcinoma.
The objective of this clinical trial is to gather more information on the efficacy and safety of Rilvegostomig in combination with bevacizumab, with or without tremelimumab, compared to the standard of care (atezolizumab in combination with bevacizumab), as well as to better understand the disease being studied and the associated health issues -
March 16, 2026Pamplona/MadridIn recruitmentEarly phase
GEM-PLASMACAR Clinical trial to evaluate the safety and efficacy of ARI0002h, a BCMA-targeted CAR-T cell therapy, for the initial treatment of patients with primary plasma cell leukemia
The GEM-PLASMACAR study is a clinical trial for people with a recent diagnosis of primary plasma cell leukemia (pPCL). In this study, we aim to determine whether ARI0002h cells are safe and effective in eliminating the disease. -
March 16, 2026Pamplona/MadridIn recruitment
TranspoCALL19 A Phase I/IIa clinical trial of an infusion of autologous peripheral blood T cells that have been expanded and transduced using Sleeping Beauty technology to express a chimeric antigen receptor with anti-CD19 specificity.
The TranspoCALL19 study is a clinical trial for people with B-cell acute lymphoblastic leukemia who have received standard treatments but still require further treatment for their disease. -
March 16, 2026PamplonaIn recruitmentEarly phase
68284528MMY2012 A Phase 2 clinical trial with multiple cohorts to better characterize the efficacy and safety of ciltacabtagene autoleucel
The aim of this study is to learn more about how cilta-cel works and its safety in treating patients with multiple myeloma, a type of cancer. In this study, there will be different groups of patients known as cohorts.